<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00145561</url>
  </required_header>
  <id_info>
    <org_study_id>UMCN-AKF 04.02</org_study_id>
    <secondary_id>MV19059</secondary_id>
    <nct_id>NCT00145561</nct_id>
  </id_info>
  <brief_title>The Pharmacokinetic Study of Saquinavir New Tablet Formulation in HIV-infected Pregnant Women.</brief_title>
  <official_title>The Pharmacokinetics of SAquinavir (Invirase New Tablet Formulation) 1,000mg + Ritonavir (Norvir) 100mg q12h in HIV-infected Pregnant Women (SARA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Radboud University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pharmacokinetic study of Saquinavir and Ritonavir in HIV-infected pregnant women&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It is generally accepted that HIV-infected pregnant women should receive treatment to prevent&#xD;
      the transmission of HIV from mother-to-child.The (relative) contra-indications for the NNRTIs&#xD;
      during pregnancy make a PI based regimen the most rational choice. Based on several&#xD;
      experiences and investigations it is expected that saquinavir will play a role as a component&#xD;
      of tripe drug regimens for HIV-infected pregnant women. Since the bid dose regimen of 1,000mg&#xD;
      saquinavir and 100mg ritonavir is approved by the regulatory authorities and with the&#xD;
      availability of a new 500mg tablet formulation of saquinavir,there is a need for a&#xD;
      well-designed pharmacokinetic trial using the new 500mg saquinavir tablet formulation in the&#xD;
      above mentioned dose.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2005</start_date>
  <completion_date type="Actual">February 2008</completion_date>
  <primary_completion_date type="Actual">January 2008</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>pharmacokinetics at week 20 and 33 of gestation and 6 weeks post partum</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>antiviral activity</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>safety</measure>
  </secondary_outcome>
  <enrollment type="Actual">40</enrollment>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saquinavir and Ritonavir</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  HIV infected woman&#xD;
&#xD;
          -  18 - 40 years of age&#xD;
&#xD;
          -  able and willing to sign Informed Consent&#xD;
&#xD;
          -  pregnant for a maximum of 31 weeks&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  history of sensitivity/idiosyncrasy to the drug&#xD;
&#xD;
          -  relevant history of interference with drug metabolism&#xD;
&#xD;
          -  inability to understand trial procedures&#xD;
&#xD;
          -  abnormal specific serum levels&#xD;
&#xD;
          -  use of specific concomitant medications&#xD;
&#xD;
          -  active hepatobiliary or hepatic disease&#xD;
&#xD;
          -  previous failure of saquinavir/ritonavir regimen&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David M Burger, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radboud University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Bonn</name>
      <address>
        <city>Bonn</city>
        <zip>53127</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Cologne</name>
      <address>
        <city>KÃ¶ln</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rijnstate Hospital</name>
      <address>
        <city>Arnhem</city>
        <zip>6815AD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Leiden</name>
      <address>
        <city>Leiden</city>
        <zip>2300RC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radboud University Medical Centre Nijmegen</name>
      <address>
        <city>Nijmegen</city>
        <zip>6500HB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erasmus Medical Centre</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital ''Germans Trias i Pujol''</name>
      <address>
        <city>Barcelona</city>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinic Rajdumri Road Pathumwan</name>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Birmingham Heartlands &amp; Sollihull Hospital</name>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chelsea and Westminster Hospital</name>
      <address>
        <city>London</city>
        <zip>SW10 9NH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>Thailand</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>https://pubmed.ncbi.nlm.nih.gov/19474478/</url>
    <description>paper</description>
  </link>
  <results_reference>
    <citation>van der Lugt J, Colbers A, Molto J, Hawkins D, van der Ende M, Vogel M, Wyen C, Schutz M, Koopmans P, Ruxrungtham K, Richter C, Burger D; SARA study team. The pharmacokinetics, safety and efficacy of boosted saquinavir tablets in HIV type-1-infected pregnant women. Antivir Ther. 2009;14(3):443-50.</citation>
    <PMID>19474478</PMID>
  </results_reference>
  <verification_date>October 2008</verification_date>
  <study_first_submitted>September 2, 2005</study_first_submitted>
  <study_first_submitted_qc>September 2, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 5, 2005</study_first_posted>
  <last_update_submitted>October 16, 2020</last_update_submitted>
  <last_update_submitted_qc>October 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2020</last_update_posted>
  <responsible_party>
    <name_title>D.M. Burger PharmD PhD, hospital pharmacist</name_title>
    <organization>Radboud University Nijmegen Medical Centre</organization>
  </responsible_party>
  <keyword>HIV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Saquinavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

